Small molecule · developed by Inventiva Pharma
Lanifibranor (also known as IVA337) is an oral drug studied in nonalcoholic steatohepatitis and type 2 diabetes mellitus.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04849728 | Phase 3 | NASH - Nonalcoholic Steatohepatitis | Active not recruiting | IVA |
| NCT05232071 | Phase 2 | NASH - Nonalcoholic Steatohepatitis | Completed | IVA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
NASH - Nonalcoholic SteatohepatitisDiabetes Mellitus, Type 2
Updated Nov 15, 2026. Something wrong or missing? Report it on the IVA page.
See IVA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IVA catalysts and pipeline →